University of California San Francisco

Kenzo Hirose headshot large
Kenzo
Hirose
MD

Associate Professor of Surgery
Division of Surgical Oncology
Director,  General Surgery Residency Program

Address

550 16th Street, #6409
San Francisco, CA 94158
United States

Email: [email protected]
Phone: 415-502-1978

    Biography

    Dr. Kenzo Hirose is a general surgeon specializing in benign and malignant conditions of the liver, pancreas and bile duct. He has a special interest in minimally invasive surgical techniques and conducts research in patient outcomes after surgery.   

    Dr. Kenzo Hirose received his medical degree from Harvard Medical school. He did his residency in general surgery at the University of California, San Francisco and his Hepatopancreatobiliary Fellowship at the Cleveland Clinic. 

     

     

    Education

    Institution Degree Dept or School End Date
    Cleveland Clinic Education Foundation Fellowship 2008
    UCSF Medical Center Residency 2006
    Harvard School of Medicine 1999

    Board Certifications

    American Board of Surgery

    Clinical Expertise

    Bile Duct Injuries
    Bile Duct Strictures
    Bile Duct Cancer (Cholangiocarcinoma)
    Gastrointestinal Carcinoid Tumor
    Gastrointestinal Stromal Tumor (GIST)
    Choledochal Cysts
    Liver Cancer (Hepatocellular Carcinoma)
    Minimally Invasive Liver & Pancreas Surgery
    Pancreatic Cancer
    Pancreatic Cysts
    Soft Tissue Sarcomas
    Liver Cysts
    Liver Metastases
    Gallbladder Cancer
    Stomach (Gastric) Cancer
    Pancreatic Neuroendocrine (Islet Cell) Tumors
    Bridging Therapies to Downstage HCC pre-Liver Transplant

    Program Affiliations

    Hepatobiliary and Pancreas Surgery Program

     

    Publications

    MOST RECENT PUBLICATIONS FROM A TOTAL OF 103
    1. Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer.
      Ejie J, Ashraf Ganjouei A, Hernandez S, Wang JJ, Romero-Hernandez F, Foroutani L, Hirose K, Nakakura E, Corvera CU, Alseidi A, Adam MA| | PubMed
    2. ASO Visual Abstract: Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
      Wong P, Pollini T, Adam MA, Alseidi A, Corvera CU, Hirose K, Kirkwood KS, Nakakura EK, Thornblade L, Maker AV| | PubMed
    3. Promoting Resident Education Priorities With an Acute Care Surgery Service Dashboard.
      Trang K, Pierce L, Wick EC, Vu L, Dicker R, Boeck MA, Garber K, Hirose K| | PubMed
    4. Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC).
      Yin H, Romero-Hernandez F, Ganjouei AA, Wang JJ, Brown A, Hirose K, Maker AV, Nakakura E, Corvera C, Kirkwood KS, Wilhelm A, Peng JS, Alseidi A, Adam MA| | PubMed
    5. Graft choice in pancreatectomy with vascular resection: equivalent safety in selected patients.
      Hoffman D, Ganjouei AA, Hernandez FR, Ifuku K, Miller P, Glencer A, Corvera C, Kirkwood K, Alseidi A, Adam M, Maker A, Hirose K, Hirose R, Nakakura EK| | PubMed
    6. ASO Visual Abstract: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
      Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK| | PubMed
    7. Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
      Wong P, Pollini T, Adam MA, Alseidi A, Corvera CU, Hirose K, Kirkwood KS, Nakakura EK, Thornblade L, Maker AV| | PubMed
    8. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
      Parikh AR, Chee BH, Tsai J, Rich TA, Price KS, Patel SA, Zhang L, Ibrahim F, Esquivel M, Van Seventer EE, Jarnagin JX, Raymond VM, Corvera CU, Hirose K, Nakakura EK, Corcoran RB, Van Loon K, Atreya CE| | PubMed
    9. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
      Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK| | PubMed
    10. Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
      Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera CU, Bergsland EK, Nakakura EK| | PubMed